From 17th to 20th September, the international biopharma and biotechnology community will converge on Shanghai for BioShanghai Week 2026 – one of the most significant gatherings in the global life sciences calendar. Micregen will be there, and we’re looking for the right people to talk to.
A Meeting Point for an Industry in Motion
BioShanghai Week isn’t a single conference so much as an ecosystem in motion for a week: scientific innovation, clinical translation, investment and industrial development all under one roof. It’s where early discoveries meet the capital and infrastructure needed to become real therapies, and where companies like Micregen get to test their thinking against the sharpest minds in the field.
For a company working at the frontier of cell-free therapeutic development, that mix is exactly the environment we need. Cell-free biology moves fast – but turning that speed into approved therapies still depends on the right partnerships: manufacturing expertise, regulatory experience, clinical development capability, and capital that understands the space.
Why We’re Going
Micregen’s visit to Shanghai follows directly from Robert Mitchell’s participation in the Pujiang Innovation Forum roundtable on 13th September, where the conversation centres on closing the gap between scientific innovation and patient impact. BioShanghai Week is the natural next step – a chance to turn that dialogue into concrete relationships.
We’re specifically keen to connect with:
- Prospective partners working on complementary technologies or platforms
- Investors with an interest in cell-free biologics and next-generation therapeutic modalities
- Service providers supporting manufacturing, scale-up or clinical development
- Organisations exploring how cell-free approaches could accelerate their own pipelines
Let’s Meet in Shanghai
If you’ll be at BioShanghai Week 2026, or simply based in Shanghai that week, we’d like to hear from you. Reach out to Robert Mitchell directly to arrange time to meet – whether that’s a formal meeting or an informal conversation over coffee.
China’s life sciences sector is growing quickly, and the opportunities for cross-border collaboration in cell-free therapeutic development have never been stronger. We’re looking forward to being part of that conversation.